NCT05515315

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 93 (estimated)
• Sponsor: Fuzhou General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)

Conditions

• Immunotherapy Esophagus Cancer

Interventions

Type	Name	Description
DRUG	Tislelizumab	Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
DRUG	Albumin paclitaxel	Participants will receive Albumin paclitaxel 260 mg/m2 , day 1 of every 3 weeks
DRUG	Nedaplatin	Participants will receive Nedaplatin 80 mg/m2 , day 1 of every 3 weeks
RADIATION	radiotherapy	50-60Gy/25-30f

Timeline

• Start date: 2022-05-31
• Primary completion: 2025-05-31
• Completion: 2027-05-31
• First posted: 2022-08-25
• Last updated: 2024-02-07

Locations

1 site across 1 country: China